Ipca Laboratories Limited
IPCALAB.NS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$495.56B
Close$
$1519.03
21.3% downside
Current Fair Value
21.3% downsideOvervalued by 21.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $495.56 Billion |
|---|---|
| Enterprise Value | $498.59 Billion |
| Annual dividend | $6.00 |
| Dividend yield | 0.31% |
| Earnings per Share | $44.98 |
| Beta | 0.04 |
| Outstanding Shares | 253,704,000 |
Return
| Return on Equity | 16.24% |
|---|---|
| Return on Assets | 10.59% |
| Return on Invested Capital | 18.43% |
Valuation & Multiples
| P/E Ratio | 37.83 |
|---|---|
| PEG | 52.31 |
| Price to Sales | 4.84 |
| Price to Book Ratio | 5.15 |
| Enterprise Value to Revenue | 4.92 |
| Enterprise Value to EBIT | 26.88 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$12.16
Consensus analyst estimateRevenue Estimate
$25.85 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$16.04
Consensus analyst estimateRevenue Estimate
$28.63 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ipca Laboratories Limited
17,210 employees
CEO: Pranay Premchand Godha
Established in Mumbai, India, in 1949, Ipca Laboratories Limited operates as a pharmaceutical enterprise focused on developing and commercializing both active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. It...